A weekly weight-loss injection lowered body mass index in children as young as 6 in a large clinical trial, according to full results presented Monday, Nov. 16, at the ObesityWeek 2026 conference and published in The New England Journal of Medicine. The drug, semaglutide, is the active ingredient in Wegovy and Ozempic.
The findings are the most detailed look yet at how the medicine works in younger children. Semaglutide is not approved in the United States for children under 12, and drugmaker Novo Nordisk, which funded the study, did not say in its announcement when or whether it will ask regulators to approve it for that age group.
What the study found
The phase 3 trial, called STEP Young, enrolled 167 children ages 6 to under 12 who had obesity. More than 85% had severe obesity when the study began. Children were randomly assigned to weekly semaglutide shots or a placebo, and every child in both groups also followed a reduced-calorie eating plan and increased physical activity, according to Novo Nordisk.
After 68 weeks, the main measurement point, the company reported these results:
- BMI fell by an average of 13.5% in the semaglutide group, while it rose 2.7% in the placebo group.
- About three in four children on semaglutide (74.7%) cut their BMI by at least 10%, compared with 4.3% on placebo.
- About 38% of children on semaglutide were no longer classified as having obesity, compared with about 2% on placebo.
Those figures count all children regardless of whether they kept taking the drug. When the company looked only at children who stuck with treatment, about 40% moved below the obesity threshold.
Yale School of Medicine physician Ania Jastreboff, the study’s lead author, said in Novo Nordisk’s announcement that the treatment was “accompanied by improvements in multiple cardiometabolic measures,” which relate to heart and metabolic health.
Side effects and open questions
Novo Nordisk said the safety profile matched earlier semaglutide studies in teens and adults and that no safety concerns were found for growth or puberty. Physician Jeremy Faust, who reviewed the paper in his Inside Medicine newsletter, noted that vomiting and diarrhea were more common with semaglutide, though they eased over time. He reported that lipase, a pancreas-related enzyme, rose more in the semaglutide group, but no child developed acute pancreatitis.
The longer-term picture is more mixed. Treatment continued to 104 weeks, and the benefit narrowed: at two years, BMI was down 9.4% on semaglutide versus up 8.4% on placebo, according to the company. Faust wrote that BMI crept up after about 68 weeks and that children gained weight back quickly after stopping the drug.
Other experts have urged caution. When early results were announced in September, NYU Langone researcher Babak Orandi told Ynet News that the fast rise in prescriptions for children means long-term monitoring is needed. A study he led in the journal Pediatrics found GLP-1 prescriptions for children ages 8 to 11 had risen 310-fold since 2019, even though the drugs are not approved for that age group, Ynet reported.
How this fits with current care
The FDA approved Wegovy for children 12 and older in December 2022. Weeks later, the American Academy of Pediatrics issued guidance saying teens 12 and older with obesity should be offered appropriate medication alongside intensive diet, exercise and lifestyle support, PBS NewsHour reported. At that time, the CDC said obesity affected nearly 20% of U.S. children and teens.
For children under 12, the main tools remain family-based changes in eating, activity and sleep, supported by a pediatric care team. The new trial does not change that, but it gives doctors and regulators much more data to weigh.
Why it matters for families
Many parents of children with obesity hear about these medicines from friends, the news or social media. Here are some points to keep in mind:
- This is not an approved use yet. Semaglutide is not approved in the U.S. for children under 12. Only a doctor can decide whether any medicine is appropriate for a child.
- Lifestyle still mattered. Every child in the trial, including those on placebo, followed a healthier eating and activity plan.
- Stopping can mean regaining. Weight came back quickly after children stopped the drug, according to the published review, which raises questions about how long treatment might last.
- Feelings matter too. Weight-related bullying and stigma can affect a child’s emotional health, advocates say, so how adults talk about weight is important.
If you are worried about your child’s weight or health, talk with your doctor or your child’s pediatrician. They can look at your child’s whole health picture and explain which options are safe and appropriate.
With Thanksgiving approaching and an early flu season spreading in several states, it is also a good time to schedule a checkup and review vaccines; the U.S. has also reportedly lost its measles elimination status.
What to watch next
Watch for whether Novo Nordisk asks the FDA and other regulators to expand semaglutide’s approval to younger children, and how pediatric groups respond to the full data. Upstormed News will follow this story.
Read more: WHO issues first type 1 diabetes guidelines for adults on World Diabetes Day
Should weight-loss medicines be an option for younger children, or is it too soon? Share your thoughts in the comments.
Sources: Novo Nordisk via BioSpace, “Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12…” (November 16, 2026); The New England Journal of Medicine, “Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age” (November 16, 2026); Inside Medicine, “New paper: Wegovy for pediatric obesity? Yes, it worked.” (November 16, 2026); Ynet News, “Weight-loss drug shows promise in children as young as 6 in early trial” (September 7, 2026); PBS NewsHour, “New guidance on childhood obesity urges medication and surgery” (January 9, 2023)

Leave a Reply